Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue.
AffiliationAcademic Department of Radiation Oncology, The University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractPositron emission tomography studies with oxygen-15-labeled water provide in vivo quantitative tissue perfusion variables-blood flow and fractional volume of distribution of water [V(d) (water)]. To investigate the relationship between perfusion variables and the effect of vascular-targeting agents on vasculature, we measured tissue perfusion in tumors, spleen, kidney, and liver before and after treatment with combretastatin-A4-phosphate, a combination of nicotinamide and carbogen (N/C), and interferon (IFN). We observed that mean tumor blood flow and V(d) (water) was lower than in kidney, liver, and spleen at baseline. Blood flow and V(d) (water) were related in tumor (r = 0.62; P = 0.004) at baseline, but not in other normal tissues evaluated, where minimal variations in V(d) (water) were observed over a wide range of blood flow. Despite the relationship between blood flow and V(d) (water) in tumors before intervention, vascular-targeting agent-induced changes in these perfusion variables were not correlated. In contrast, changes in blood flow and V(d) (water) correlated in kidney and spleen after N/C and in kidney after combretastatin-A4-phosphate. The close relation between blood flow and V(d) (water) in tumors but not normal tissue may reflect barriers to fluid exchange in tumors because of necrosis and/or increased interstitial fluid pressure and underlies the importance and interdependence of these positron emission tomography perfusion variables under these conditions. As blood flow and V(d) (water) signify different aspects of tissue perfusion, the differential effects of interventions on both variables, flow and V(d) (water), should therefore be reported in future studies.
CitationBlood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. 2009, 8 (2):303-9 Mol. Cancer Ther.
JournalMolecular Cancer Therapeutics
- Human tumor blood flow is enhanced by nicotinamide and carbogen breathing.
- Authors: Powell ME, Hill SA, Saunders MI, Hoskin PJ, Chaplin DJ
- Issue date: 1997 Dec 1
- Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.
- Authors: Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM
- Issue date: 2003 Aug 1
- Effects of the interaction between carbogen and nicotinamide on R3230 Ac tumor blood flow in Fischer 344 rats.
- Authors: Braun RD, Lanzen JL, Turnage JA, Rosner G, Dewhirst MW
- Issue date: 2001 May
- Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.
- Authors: Gupta N, Saleem A, Kötz B, Osman S, Aboagye EO, Phillips R, Vernon C, Wasan H, Jones T, Hoskin PJ, Price PM
- Issue date: 2006 May 15
- Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined.
- Authors: Honess DJ, Bleehen NM
- Issue date: 1995 Jun